Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 394 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Open Angle Clear all

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: Glaucoma therapy; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2003
U.S. locations: 1
States / cities: Multiple Locations Throughout the US Sponsored by Alcon of, Texas

Conditions: Open Angle Glaucoma
Interventions: Not listed
Lead sponsor: Wills Eye; Other
Eligibility: 45 Years to 85 Years
Enrollment: 101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: Xalatan; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Glaucoma
Interventions: iStent Inject (GTS400), Cataract Surgery; Device · Procedure
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 22
States / cities: Rogers, Arkansas • Petaluma, California • Parker, Colorado + 19 more

Conditions: Open Angle Glaucoma
Interventions: Not listed
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Primary Open-angle Glaucoma
Interventions: PRESERFLO® MicroShunt, Trabeculectomy; Device · Procedure
Lead sponsor: InnFocus Inc.; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 279 participants
Timeline: 2020 – 2022
U.S. locations: 19
States / cities: Glendale, Arizona • Fayetteville, Arkansas • Los Angeles, California + 16 more

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 40 Years to 89 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Primary Open Angle Glaucoma, Pseudoexfoliative Glaucoma, Chronic Angle Closure Glaucoma
Interventions: Not listed
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 40 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: NCX 470 0.1%, Latanoprost 0.005%; Drug
Lead sponsor: Nicox Ophthalmics, Inc.; Industry
Eligibility: 18 Years to 84 Years
Enrollment: 696 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 63
States / cities: Dothan, Alabama • Chandler, Arizona • Phoenix, Arizona + 54 more

Conditions: Open Angle Glaucoma (OAG)
Interventions: VisiPlate Glaucoma Implant; Device
Lead sponsor: Avisi Technologies Inc.; Industry
Eligibility: 45 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 12
States / cities: Glendale, Arizona • Los Angeles, California • Petaluma, California + 7 more

Conditions: Ocular Hypertension, Open-Angle Glaucoma
Interventions: Latanoprost Punctal Plug Delivery System, Xalatan; Drug
Lead sponsor: Mati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Menlo Park, California

Conditions: Primary Open Angle Glaucoma
Interventions: GlaucoCetin, Placebo; Dietary Supplement · Other
Lead sponsor: Wills Eye; Other
Eligibility: 40 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Ocular Hypertension, Open Angle Glaucoma
Interventions: BOL-303259-X, Timolol maleate; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 40 Years to 90 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: PG286 Ophthalmic Solution 0.5%, AR-12286 Ophthalmic Solution 0.5%, Travoprost Ophthalmic Solution 0.004%; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 21
States / cities: Artesia, California • Inglewood, California • Newport Beach, California + 18 more

Conditions: Glaucoma, Open-Angle [C11.525.381.407]
Interventions: Open angle glaucoma - iDropper device; Device
Lead sponsor: Care Team Solutions; Industry
Eligibility: 21 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Primary Open Angle Glaucoma, Ocular Hypertension
Interventions: DE-126 Ophthalmic Solution 0.002% QD, Timolol Maleate Ophthalmic Solution 0.5% BID; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 41
States / cities: Chandler, Arizona • Phoenix, Arizona • Sun City, Arizona + 34 more

Conditions: Glaucoma and Ocular Hypertension
Interventions: Brimonidine Tartrate 0.025%, Vehicle; Drug
Lead sponsor: Eye Therapies, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Winchester, Massachusetts

Conditions: Primary Open-angle Glaucoma (POAG) Patient
Interventions: SENSIMED Triggerfish®; Device
Lead sponsor: Sensimed AG; Industry
Eligibility: 40 Years to 89 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Open Angle Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma
Interventions: iStent infinite trabecular micro-bypass system model iS3, iDose TR (Travoprost intracameral Implant) 75mcg; Device · Drug
Lead sponsor: Jonathon Myers; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Glaucoma, Glaucoma Open-Angle
Interventions: Eyetronic rtACS, Sham rtACS; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Glaucoma, Open Angle, Low Risk, Ocular Hypertension, Glaucoma Suspect
Interventions: Mercury™ Multi-Pressure Dial (MPD) Experimental Goggle, Mercury™ Multi-Pressure Dial (MPD) Placebo Goggle; Device
Lead sponsor: Vance Thompson Vision; Other
Eligibility: 22 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Glaucoma, Open-Angle
Interventions: Not listed
Lead sponsor: Glaukos Corporation; Industry
Eligibility: Not listed
Enrollment: 475 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 24
States / cities: Glendale, Arizona • Fayetteville, Arkansas • Santa Rosa, California + 20 more

Conditions: Primary Open-angle Glaucoma
Interventions: Questionnaires; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Open Angle Glaucoma, Primary Open Angle Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma in Both Eyes
Interventions: Glaucoma and Cataract Surgery; Procedure
Lead sponsor: Wills Eye; Other
Eligibility: 40 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension Patients

Does the Optic Disc Grading Done Visually by Your Doctor Agree With Optic Nerve Testing Which is Done by Machines?

Dose Response Study of AL-37807 Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension

GTS400 Stent Implantation in Conjunction With Cataract Surgery in Subjects With Open-angle Glaucoma

Determinants of Compliance With Glaucoma Therapy

PRESERFLO® MicroShunt Extension Study

The Effect of Omega-3 Fatty Acid Supplementation on Intraocular Pressure & Ocular Surface

Advanced Glaucoma Progression Study

MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Safety and Effectiveness of the VisiPlate Aqueous Shunt in Patients With Refractory Open-Angle Glaucoma

A Study of the L-PPDS With Adjunctive Xalatan® Eye Drops in Subjects With OH or OAG

Vision Preservation and Restoration Following a 6 Month Trial of GlaucoCetin

BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension

A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days

iDropper Usability in Glaucoma

Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Study Evaluating the Safety and Intraocular Pressure (IOP) Lowering Response of Brimonidine Tartrate Ophthalmic Solution in Subjects With Open Angle Glaucoma or Ocular Hypertension

Intraocular Pressure (IOP) Patterns in Fast Versus Slow Visual Field (VF) Progression Patients

Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma

Electrical Stimulation for Vision Neuroenhancement in Glaucoma

Effect of Negative Pressure on Pattern Electroretinography Readings

iStent Inject Trabecular Micro-Bypass System Continuation Post-Approval Study

Impact of Glaucoma and Visual Field Loss on Life Space

IOP and Medication Reduction in MIGS Procedures